Invasive Breast Carcinoma Clinical Trials

18 recruiting

Invasive Breast Carcinoma Trials at a Glance

19 actively recruiting trials for invasive breast carcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Houston, New York, and Grand Rapids. Lead sponsors running invasive breast carcinoma studies include M.D. Anderson Cancer Center, National Cancer Institute (NCI), and City of Hope Medical Center.

Browse invasive breast carcinoma trials by phase

Treatments under study

About Invasive Breast Carcinoma Clinical Trials

Looking for clinical trials for Invasive Breast Carcinoma? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Invasive Breast Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Invasive Breast Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 2

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaInvasive Breast Carcinoma
National Cancer Institute (NCI)70 enrolled30 locationsNCT03606967
Recruiting
Not Applicable

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+20 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT02918474
Recruiting

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

Invasive Breast CarcinomaInflammatory Breast CarcinomaSecond Primary Malignant Neoplasm
M.D. Anderson Cancer Center1,200 enrolled10 locationsNCT00477100
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled1 locationNCT07137416
Recruiting

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Breast CarcinomaInvasive Breast Carcinoma
M.D. Anderson Cancer Center20 enrolled1 locationNCT05406232
Recruiting

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Head and Neck CarcinomaMalignant Solid NeoplasmSarcoma+59 more
Alliance for Clinical Trials in Oncology2,000 enrolled745 locationsNCT05334069
Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Ovarian CarcinomaEsophageal CarcinomaGastric Carcinoma+26 more
National Cancer Institute (NCI)1,600 enrolled152 locationsNCT04314401
Recruiting

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerNeoadjuvant TherapyInvasive Breast Carcinoma+2 more
Atlas University80 enrolled1 locationNCT07289282
Recruiting
Not Applicable

NearWave Optical Molecular Monitoring

Breast CancerHER2-negative Breast CancerHER2-positive Breast Cancer+2 more
Indiana University15 enrolled1 locationNCT06744465
Recruiting
Phase 4

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+2 more
University of Washington68 enrolled1 locationNCT05183828
Recruiting
Phase 3

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
City of Hope Medical Center200 enrolled3 locationsNCT06763328
Recruiting
Not Applicable

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Anatomic Stage 0 Breast Cancer AJCC v8Invasive Breast CarcinomaAnatomic Stage 1 Breast Cancer AJCC v8+3 more
Thomas Jefferson University80 enrolled1 locationNCT04959474
Recruiting
Phase 1

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8Recurrent Breast CarcinomaInvasive Breast Carcinoma+2 more
Mayo Clinic54 enrolled1 locationNCT04521764
Recruiting
Not Applicable

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in IBC

Sentinel Lymph Node Biopsy (SLNB)Invasive Breast CarcinomaNeoadjuvant Chemotherapy
European Institute of Oncology75 enrolled1 locationNCT07080944
Recruiting

Breast Cancer Survivorship Biorepository

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
University of Southern California1,300 enrolled1 locationNCT05786664
Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Bladder CarcinomaEsophageal CarcinomaNon-small Cell Lung Cancer+13 more
Guardant Health, Inc.2,020 enrolled57 locationsNCT05059444
Recruiting
Early Phase 1

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Emory University40 enrolled4 locationsNCT05464810
Recruiting
Phase 1Phase 2

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+17 more
Jonsson Comprehensive Cancer Center18 enrolled1 locationNCT05319873
Recruiting
Phase 2

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Stage III Breast CancerTriple-Negative Breast CarcinomaRecurrent Breast Carcinoma+6 more
Laura Huppert, MD, BA150 enrolled12 locationsNCT03971409